OSI Pharmaceuticals, Inc. Presents Positive Results From Phase IIa Clinical Trial Of Its DPIV Inhibitor, PSN9301, At Annual Meeting Of American Diabetes Association

MELVILLE, NY--(BUSINESS WIRE)--June 12, 2006--(OSI) Pharmaceuticals (NASDAQ: OSIP - News) presented the positive results from its Phase IIa proof-of-concept study with its dipeptidyl peptidase-IV (DPIV) inhibitor, PSN9301, at the annual meeting of the American Diabetes Association in Washington, DC. The study demonstrated that with prandial (with-meal) dosing, 14-day administration of PSN9301 reduced blood glucose levels in patients with type 2 diabetes and was generally well-tolerated with no episodes of hypoglycemia (low blood glucose). Also presented were preclinical data on novel, orally available agonists of the G-protein coupled receptor GPR119 for the potential treatment of obesity, diabetes and associated metabolic disorders.
MORE ON THIS TOPIC